Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer

Lagheden, Camilla; Eklund, Carina; Lamin, Helena; Kleppe, Sara Nordqvist; Lei, Jiayao; Elfström, K. Miriam; Sundström, Karin; Andrae, Bengt; Sparén, Pär; Dillner, Joakim

doi:10.1038/s41416-018-0053-6

Cited by 63 publications

(60 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the Walboomers’ study included predominantly squamous cancers, with a small number of adenocarcinomas and adenosquamous cancers . The Australian figure of 92.9% reported in 2017 aligns with recent studies in other countries which cite figures for the percentage of cervical cancers testing positive for HPV of 92.3% (pooled data worldwide for 2006–2010), 90.6% (United States), and 86.2% (Sweden) …”

Section: Proportion Of Hpv‐positive Cervical Cancers In Australiasupporting

confidence: 63%

Understanding the proportion of cervical cancers attributable to HPV

Brotherton

Budd

Saville

2020

Medical Journal of Australia

View full text Add to dashboard Cite

PerspectivesUnderstanding the proportion of cervical cancers attributable to HPV Most cervical cancers can be prevented with HPV vaccination and screening S ince Walboomers and colleagues 1 published their findings in 1999, citing that 99.7% of cervical cancers are related to the human papillomavirus (HPV), this has become the standard understanding of the proportion of cervical cancers attributable to HPV.Two decades later, and with both HPV vaccination and HPV-based screening programs in place to prevent cervical cancer in Australia, it is prudent to review the available evidence to understand the potential for cervical cancer prevention through HPV-based public health interventions.

show abstract

Section: Proportion Of Hpv‐positive Cervical Cancers In Australiasupporting

confidence: 63%

Understanding the proportion of cervical cancers attributable to HPV

Brotherton

Budd

Saville

2020

Medical Journal of Australia

View full text Add to dashboard Cite

show abstract

“…The importance of HPV58 has been investigated by many research groups, and it has been unanimously concluded that HPV58 accounts for a remarkably higher proportion of cervical cancer in East Asia than elsewhere. For instance, HPV58 was found in 29% of HPV‐positive cervical squamous cell carcinomas (SCC) in Shanghai (East China), 21% in Taiwan, 19% in South Korea, 14% in Japan, 13% in south Sichuan (southwestern China), 10% in Hong Kong (east China) and 9% in Yangtze River Delta region (east China) but only 0.6%‐2.8% outside East Asia . HPV58 is therefore the second or third most prevalent HPV type in East Asia, even though it only ranks sixth or seventh worldwide .…”

Section: Introductionmentioning

confidence: 99%

“…Japan, 13 13% in south Sichuan (southwestern China), 14 10% in Hong Kong (east China) 15 and 9% in Yangtze River Delta region (east China) 16 but only 0.6%-2.8% outside East Asia. 17,18 HPV58 is therefore the second or third most prevalent HPV type in East Asia, 3,8,18 even though it only ranks sixth or seventh worldwide. 5 Furthermore, our meta-analysis scrutinising 219 publications from 1994 to 2012 found that attribution of HPV58 to cervical cancer was 3.7-fold higher in East Asia than elsewhere, even after adjustment for bystander effect in multiple-type infections.…”

mentioning

confidence: 99%

Oncogenic comparison of human papillomavirus type 58 E7 variants

Law

Boon

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Human papillomavirus 58 (HPV58) ranks the second or third in East Asian cervical cancers. Current studies on HPV58 are scarce and focus on the prototype. Previously, we identified the three most common circulating HPV58 E7 strains contained amino acid alterations: G41R/G63D (51%), T20I/G63S (22%) and T74A/D76E (14%) respectively. Among them, the T20I/G63S variant (V1) had a stronger epidemiological association with cervical cancer. We therefore suggested that V1 possessed stronger oncogenicity than the other two variants. Here, we performed phenotypic assays to characterize and compare their oncogenicities with HPV58 E7 prototype. Our results showed that overexpression of V1 conferred a higher colony‐forming ability to primary murine epithelial cells than prototype (P < 0.05) and other variants, implicating its higher immortalising potential. Further experiments showed that both V1 and prototype enhanced the anchorage‐independent growth of NIH/3T3 cells (P < 0.001), implicating their stronger transforming power than the two other variants. Moreover, they possessed an increased ability to degrade pRb (P < 0.001), which is a major effector pathway of E7‐driven oncogenesis. Our work represents the first study to compare the oncogenicities of HPV58 E7 prototype and variants. These findings deepened our understanding of HPV58 and might inform clinical screening and follow‐up strategy.

show abstract

“…All samples were HPV genotyped using MGP-PCR, primer targeting L1, and type-specific probes using Luminex detection technology, as previously described (34)(35)(36). Briefly, 5 µL aliquots of extracted DNA were used in the MGP-PCR in a total volume of 25 µL.…”

Section: Mgp-pcr and Hpv Typing Using Luminexmentioning

confidence: 99%

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

Ejegod

Lagheden

Bhatia

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary screening.Methods The CLART® HPV4S (CLART4S) assay is a newly developed full-genotyping assay detecting 14 oncogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and two non-oncogenic HPV genotypes (6, 11). It was evaluated using SurePath and ThinPrep screening samples collected from the Danish and Swedish cervical cancer screening programs, respectively. For calculation of sensitivity, 81 SurePath and 80 ThinPrep samples with confirmed ≥CIN2 were assessed. For clinical specificity analysis, 1,184 SurePath and 1,169 ThinPrep samples from women with <CIN2 histology were assessed. Sensitivity and specificity of the CLART4S assay was compared to an established reference test; the MGP-PCR (Modified General Primers GP5+/6+ with genotyping using Luminex). Inter and intra laboratory reproducibility of the assay was assessed using 540 SurePath and 520 ThinPrep samples, respectively. The genotype concordance between CLART4S and MGP-PCR was also assessed.Results In SurePath samples, the sensitivity of CLART4S was 0.90 (MGP-PCR =0.93) and the specificity was 0.91 (MGP-PCR=0.91); In ThinPrep samples the sensitivity of CLART4S was 0.98 (MGP-PCR=1.00) and specificity was 0.94 (MGP-PCR =0.87). The CLART4S was shown to be non-inferior to that of MGP-PCR for both sensitivity (p=0.002; p=0.01) and specificity (p=0.01; p=0.00) in SurePath and ThinPrep samples, respectively. Intra-laboratory reproducibility and inter-laboratory agreement was met for both media types. The individual genotype concordance between CLART4S and MGP-PCR was good agreement for almost all 14 HPV genotypes in both media types.Conclusions The CLART4S assay was proved non-inferior to the comparator assay MGP-PCR for both sensitivity and specificity using SurePath and ThinPrep cervical cancer screening samples from the Danish and Swedish screening programs, respectively. This is the first study to demonstrate clinical validation of a full-genotyping HPV assay conducted in parallel on both SurePath and ThinPrep collected samples.

show abstract

Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer

Abstract: We present one of the largest series of HPV-genotyped cervical cancers to date. The systematic collection of cervical cancer HPV genotyping data by the screening registry will facilitate prevention and monitoring of HPV type-specific disease burden.

Cited by 63 publications

References 16 publications

Understanding the proportion of cervical cancers attributable to HPV

Understanding the proportion of cervical cancers attributable to HPV

Oncogenic comparison of human papillomavirus type 58 E7 variants

Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

Contact Info

Product

Resources

About